多柔比星单药对比多柔比星联合曲贝替定后续曲贝替定单药一线治疗转移性或不可切除平滑肌肉瘤(LMS-04):随机、多中心、开放标签3期试验
LMS-04研究在法国20家中心纳入150例转移性或不可切除子宫或软组织平滑肌肉瘤患者,1:1随机接受多柔比星单药或多柔比星联合曲贝替定后续曲贝替定维持治疗。联合组中位无进展生存期显著长于单药组(12.2个月 vs 6.2个月,校正HR 0.41,P<0.0001),但3-4级血液学不良事件更常见。
要点
- 多柔比星联合曲贝替定组中位PFS为12.2个月,多柔比星单药组为6.2个月,校正HR 0.41。
- 联合组3-4级中性粒细胞减少80%、贫血31%、血小板减少47%、发热性中性粒细胞减少28%。
- 作者认为联合方案可考虑作为转移性平滑肌肉瘤的一线治疗选择。
核心结论
- 多柔比星联合曲贝替定一线治疗转移性或不可切除平滑肌肉瘤较多柔比星单药显著延长无进展生存期,毒性更高但可控,作者认为可考虑作为转移性平滑肌肉瘤一线治疗的选择。
研究设计与样本
- LMS-04为随机、多中心、开放标签、优效性3期试验,纳入法国20家法国肉瘤协作组中心的患者。
- 纳入年龄≥18岁、ECOG体能状态0-1、既往未接受化疗的转移性或复发不可切除平滑肌肉瘤患者。
- 共150例患者(子宫平滑肌肉瘤67例,软组织平滑肌肉瘤83例)1:1随机:多柔比星单药组76例,多柔比星联合曲贝替定组74例。
- 多柔比星单药组:静脉多柔比星75 mg/m²,每3周一次,最多6周期。
- 联合组:静脉多柔比星60 mg/m²联合静脉曲贝替定1.1 mg/m²,每3周一次,最多6周期,后续曲贝替定单药维持治疗;两组6周期后均允许对残留病灶手术。
主要发现
- 中位随访时间:多柔比星单药组36.9个月(IQR 30.0-43.2),联合组38.8个月(IQR 32.7-44.2)。
- 中位无进展生存期:联合组12.2个月(95%CI 10.1-15.6)vs 单药组6.2个月(95%CI 4.1-7.1),校正HR 0.41(95%CI 0.29-0.58),P<0.0001。
- 3-4级不良事件:中性粒细胞减少单药组10/75例(13%)vs 联合组59/75例(80%);贫血4例(5%)vs 23例(31%);血小板减少0例 vs 35例(47%);发热性中性粒细胞减少7例(9%)vs 21例(28%)。
- 严重不良事件:单药组9例(12%),联合组15例(原文写作201%,按上下文应为20%)。
- 治疗相关死亡仅1例,见于多柔比星单药组(心脏衰竭)。
关键数值与推荐
- 主要终点为盲法独立中心评审根据RECIST 1.1评估的无进展生存期。
- 疗效分析基于意向治疗人群(全部随机患者),安全性人群为至少接受1周期治疗的随机患者。
临床怎么用
- 作者认为多柔比星联合曲贝替定可考虑作为转移性平滑肌肉瘤的一线治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin has shown promising results in phase 1 and 2 studies. We aimed to identify and compare the progression-free survival of patients with metastatic or unresectable uterine or soft tissue leiomyosarcoma treated with doxorubicin and trabectedin combined as first-line therapy versus doxorubicin alone in a phase 3 trial. METHODS: LMS-04 was a randomised, multicentre, open-label, superiority phase 3 trial, which included patients from 20 centres of the French Sarcoma Group (anticancer centers or hospitals with an oncological unit) in France. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 0-1, and had metastatic or relapsed unresectable leiomyosarcomas that had not previously been treated with chemotherapy. Patients were randomly assigned (1:1), by means of an interactive web response system (permuted blocks of different sizes from two to six), to receive either intravenous doxorubicin alone (75 mg/m2) once every 3 weeks for up to six cycles or of intravenous doxorubicin (60 mg/m2) plus intravenous trabectedin (1·1 mg/m2) once every 3 weeks up to six cycles followed by maintenance with trabectedin alone. Surgery for residual disease was allowed in both groups after six cycles of treatment. Randomisation was stratified by tumour location (uterine vs soft tissue) and disease (locally advanced vs metastatic). The primary endpoint was progression-free survival assessed by blinded independent central review and according to Response Evaluation Criteria in Solid Tumours 1.1 criteria. Efficacy analyses were performed on all randomly assigned patients, based on the intention-to-treat principle. The safety population included all randomly assigned patients who received at least one cycle of treatment. This trial is registered with ClinicalTrials.gov, NCT02997358, and is closed to enrolment. FINDINGS: Between Jan 18, 2017, and March 21, 2019, 150 patients were enrolled (67 with uterine leiomyosarcomas and 83 with soft tissue leiomyosarcomas) and included in the intention-to-treat population: 76 in the doxorubicin alone group and 74 in the doxorubicin plus trabectedin group. The median duration of follow-up was 36·9 months (IQR 30·0-43·2) in the doxorubicine group and 38·8 months (32·7-44·2) in the doxorubicin plus trabectedin group. Median progression-free survival was significantly longer with doxorubicin plus trabectedin versus doxorubicin alone (12·2 months [95% CI 10·1-15·6] vs 6·2 months [4·1-7·1]; adjusted hazard ratio 0·41 [95% CI 0·29-0·58]; p<0·0001). The most common grade 3-4 adverse events were neutropenia (ten [13%] of 75 patients in the doxorubicin alone group vs 59 [80%] in the doxorubicin plus trabectedin group), anaemia (four [5%] vs 23 [31%]), thrombocytopenia (0 vs 35 [47%]), and febrile neutropenia (seven [9%] vs 21 [28%]). Nine (12%) patients in the doxorubicin alone group and 15 (201%) patients in the doxorubicin plus trabectedin group has serious adverse events. There was only one treatment-related death, reported in the doxorubicin alone group (cardiac failure). INTERPRETATION: Doxorubicin plus trabectedin in first-line therapy was found to significantly increase progression-free survival in patients with metastatic or unresectable leiomyosarcomas compared with doxorubicin alone, despite a higher but manageable toxicity, and could be considered an option for the first-line treatment of metastatic leiomyosarcomas. FUNDING: PharmaMar.
引用
- Pautier P, Italiano A, Piperno-Neumann S, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022. PMID: 35835135. doi:10.1016/S1470-2045(22)00380-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。